(lp0
S"Intercept Pharmaceuticals Inc  Stock Could Be Biotech's Grand Slam Investorplace.com - Jan 24, 2017 The market has begun 2017 trading sideways, but don't let that fool you into thinking there aren't opportunities out there, especially in biotech."
p1
aS"This Analyst Bullish On Intercept Pharmaceuticals Inc  Long-Term Smarter Analyst - Feb 10, 2017 Intercept Pharmaceuticals Inc  shares rose as much as 9% during Friday's trading session, after the drug maker announced changes to its ongoing Ocaliva Phase 3 trial in NASH that increase probability of completing enrollment for interim&nbsp;...Intercept Pharma  to Provide Update on Phase 3 REGENERATE Trial of OCA ... - StreetInsider.comIs Intercept Pharmaceuticals Inc  Stock A Buy After OCA Update? - BNL Finance   "
p2
aS"What's Happening To These Stocks?  Intercept Pharmaceuticals, Inc. (ICPT ... Post Analyst - 18 hours ago The company's consensus rating on Reuter's scale remained unchanged from 2.5 to 2.5 during a month. Analysts set a 12-month price target of $42.25 a share.Intercept Pharmaceuticals Inc  Shares Bought by Ladenburg Thalmann ... - Community Financial News"
p3
aS'Analyst Target Price Look at Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT ... Sherwood Daily - 16 hours ago Intercept Pharmaceuticals, Inc.  shares have been labeled a top pick by Beta Research as it meets the A+ criteria outlined by the firm.'
p4
aS'Charles Payne on Biotech: Biogen Inc , Intercept Pharmaceuticals Inc  Investorplace.com - Nov 29, 2016 Still, I am not interested in chasing drug names, as most of the large pharmaceutical companies have thin product pipelines and aging blockbusters.'
p5
aS"Intercept Pharmaceuticals Reports Third Quarter 2016 Financial Results and ... GlobeNewswire  - Nov 3, 2016 NEW YORK, Nov. 03, 2016  -- Intercept Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today&nbsp;...Intercept Pharmaceuticals'  CEO Mark Pruzanski on Q3 2016 Results ... - Seeking AlphaIntercept  Reports Narrower-Than-Expected Q3 Loss November 03, 2016 - Zacks.com"
p6
aS"Blog Coverage Intercept Pharmaceuticals Received NICE Approval for Ocaliva for ... Yahoo Finance - Mar 3, 2017 LONDON, UK / ACCESSWIRE / March 3, 2017 / Active Wall St. blog coverage looks at the headline from Intercept Pharmaceuticals, Inc.  as the Company announced on March 01, 2017, that UK's National Institute for Health and Care&nbsp;..."
p7
aS"Intercept Pharmaceuticals Inc  Rating Reiterated by Wedbush The Cerbat Gem - Mar 21, 2017 Intercept Pharmaceuticals logo Intercept Pharmaceuticals Inc 's stock had its outperform rating reissued by Wedbush in a research report issued to clients and investors on Friday.Intercept Pharmaceuticals Inc  Given Consensus Rating of Hold by ... - Sports Perspectives"
p8
aS'Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and ... GlobeNewswire  - Feb 23, 2017 NEW YORK, Feb. 23, 2017  -- Intercept Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today&nbsp;...Intercept Pharmaceuticals  Q4 2016 Results - Earnings Call Transcript - Seeking AlphaINTERCEPT PHARMACEUTICALS, INC.  Files An 8-K Results of ... - Market Exclusive'
p9
aS'Intercept Pharmaceuticals Inc  Receives $176.25 Average Target Price ... The Cerbat Gem - Mar 19, 2017 Intercept Pharmaceuticals logo Intercept Pharmaceuticals Inc  has been given a consensus recommendation of Hold by the twenty analysts that are presently covering the firm.'
p10
a.